Share on StockTwits

Analysts’ ratings reiterations for Tuesday, August 12th:

The Boeing Company (NYSE:BA) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $127.00 target price on the stock. Zacks’ analyst wrote, “We are maintaining our recommendation on Boeing at Neutral following its second quarter earnings release. The company’s bottom line was above the Street expectation while the top line missed the same. It reported impressive second quarter earnings as strong commercial margins, large tax settlements and large buybacks offset soft revenues and a charge on the KC-46. Although its defense segment experienced a margin contraction, sequestration and budget cuts notwithstanding, this section continued to win substantial defense orders. Boeing’s strong balance sheet and cash flows provide financial flexibility for incremental dividend, ongoing share repurchases and earnings accretive acquisitions. Nevertheless, this defense giant faces the risk of U.S. defense budget cuts, the uncertain fate of high-cost programs, risks related to key project executions and order cancellations. “

CIGNA (NYSE:CI) had its neutral rating reissued by analysts at Zacks. The firm currently has a $95.00 target price on the stock. Zacks’ analyst wrote, “Cigna Corp. reported second-quarter 2014 earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.85. Earnings were also up 10.1% year over year. Cigna’s better-than-expected earnings came from premium growth across all its business segments. Over the longer term, the company is set to benefit from its differentiated portfolio of businesses. Its strong global supplemental business, Pharmacy Benefit Management (“PBM”) Services Agreement, organizational efficiency plans as well as expansion of Seniors and Medicare business with the acquisition of HealthSpring are likely to drive growth going forward. A strong balance sheet and investment grade ratings are the other positives. However, the company continues to face pressure from the medicare advantage rate cut, higher medical cost and rising expenses. We thus maintain our Neutral recommendation on the stock.”

Mack Cali Realty Corp (NYSE:CLI) had its neutral rating reissued by analysts at Zacks. The firm currently has a $22.00 price target on the stock.

CenturyLink (NYSE:CTL) had its outperform rating reiterated by analysts at Macquarie. Macquarie currently has a $43.00 target price on the stock, up from their previous target price of $42.00.

CVS Caremark (NYSE:CVS) had its neutral rating reissued by analysts at Zacks. The firm currently has a $82.00 price target on the stock. Zacks’ analyst wrote, “CVS posted a decent second-quarter 2014 with 16.5% year over year rise in adjusted EPS to $1.13 which also surpassed the Zacks Consensus Estimate by $0.03 as well as the company-provided guidance range of $1.08 to $1.11. Net revenue on the other hand, increased 10.7% to $34.6 billion, edging past the Zacks Consensus Estimate of $33.41 billion. The generic wave in the pharmaceutical industry continues to work in CVS’ favor, as seen in the consistent margin expansion of the company. We are also impressed with CVS’ strong guidance for 2014 where increased adjusted EPS reflects strong year-over-year growth and the company’s optimism about the future. On the contrary, the decline in front-end sales was disappointing. Moreover, the competitive landscape remains tough. We also keep an eye on the tussle for market share gain in the PBM as well as retail pharmacy segment. Thus, we reiterate our Neutral recommendation on the stock.”

Caesars Entertainment Corp (NYSE:CZR) had its neutral rating reissued by analysts at Macquarie. Macquarie currently has a $12.00 price target on the stock, up from their previous price target of $8.00.

Dendreon (NASDAQ:DNDN) had its sell rating reaffirmed by analysts at Roth Capital.

eBay (NASDAQ:EBAY) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $57.00 price target on the stock. Zacks’ analyst wrote, “eBay is one of the largest online retailers in the world. The company’s profits increased post second quarter earnings results driven by strength in Paypal. Despite the temporary challenges in the Marketplaces segment, a focus on buying experience, a strong Payments segment, opportunities in the fast-growing mobile space, international expansion and a strong balance sheet remain positives. However, growing competition and increased investments on the Payments side and execution risks overall could impact results this year. We therefore reiterate our Neutral rating on the shares.”

Emergent Biosolutions (NYSE:EBS) had its neutral rating reiterated by analysts at Zacks. They currently have a $25.00 price target on the stock. Zacks’ analyst wrote, “Emergent BioSolutions’ second quarter 2014 earnings of $0.24 per share fell short of the Zacks Consensus Estimate by 2 cents. Quarterly earnings were below the year-ago figure by 17.2%. The year-over-year decline was primarily due to higher costs incurred in the reported quarter. We are encouraged by the company s decision to expand BioThrax’s label. We are positive on Emergent BioSolutions’ acquisition of Cangene as it has significantly expanded the company’s product portfolio/pipeline. We believe that the stock is fairly valued at current levels with limited scope for upside. Consequently, we retain our Neutral recommendation on the Zacks Ranked #3 (Hold) stock.”

Guardian Capital Group (TSE:GCG) had its sector perform rating reissued by analysts at Scotiabank. They currently have a C$19.00 target price on the stock.

Globalstar (NASDAQ:GSAT) had its buy rating reaffirmed by analysts at Chardan Capital.

IMAX (NASDAQ:IMAX) had its neutral rating reiterated by analysts at Zacks. They currently have a $28.00 target price on the stock. Zacks’ analyst wrote, “IMAX Corp. posted strong financial results for the second quarter of 2014. Both the top and the bottom line outpaced the respective Zacks Consensus Estimate. Hit Hollywood releases, increasing theater installations, higher backlogs and growing presence in China will continue to spur growth for the company moving ahead. Moreover, signing of new deals with Nordic Cinema and Ster-Kinekor will further boost IMAX’s top line. However, an unpredictable movie business, volatile European markets and continuous technological changes may act as headwinds for IMAX. We also believe that the stock is fairly valued at current levels. Therefore, we maintain our long-term Neutral recommendation on IMAX Corp.”

Mattress Firm Holding Corp (NASDAQ:MFRM) had its buy rating reiterated by analysts at Nomura. The firm currently has a $60.00 target price on the stock, up from their previous target price of $56.00.

Priceline Group (NASDAQ:PCLN) had its neutral rating reissued by analysts at Zacks. The firm currently has a $1,375.00 target price on the stock. Zacks’ analyst wrote, “Priceline.com is one of the leading online travel companies in the world. Priceline’s second quarter results exceeded the Zacks Consensus Estimates and forward guidance was above estimates. The secular growth trend in the online travel space, Priceline’s international growth opportunities, good execution, prudent marketing strategy and strong financial position are likely to drive upside to the shares. Of course, currency issues, macro headwinds, continued investments and occupancy tax-related litigation remain overhangs. We therefore reiterate our Neutral recommendation on Priceline shares.”

Sigma-Aldrich (NASDAQ:SIAL) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $107.00 target price on the stock.

Sony (NYSE:SNE) had its buy rating reissued by analysts at Jefferies Group. The firm currently has a $23.90 target price on the stock, up from their previous target price of $20.80.

Sorrento Therapeutics (NASDAQ:SRNE) had its outperform rating reaffirmed by analysts at Zacks. The firm currently has a $22.50 price target on the stock. Zacks’ analyst wrote, “Sorrento is a biopharmaceutical company focused on cancer. Its lead candidate Cynviloq, a competitor to Abraxane , has advanced to the pivotal trial using 505(b)(2) pathway. The second lead program Resiniferatoxin (RTX) is in mid-stage development for cancer pain. Sorrento also owns two drug development platforms: G-MAB and antibody drug conjugates (ADCs), which target the therapeutic antibody market. Both G-MAB and ADCs have great potential for partnerships that could provide near term revenue for the Company. We are optimistic about the prospect of Sorrento and rate its shares Outperform. “

TCP Capital Corp (NASDAQ:TCPC) had its market outperform rating reissued by analysts at Jefferies Group. Jefferies Group currently has a $18.00 price target on the stock, up from their previous price target of $17.50.

Williams Companies (NYSE:WMB) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $60.00 price target on the stock. Zacks’ analyst wrote, “Williams Companies has spent $6.0 billion to procure full general partner (GP) ownership and 50% limited partner (LP) interest in Access Midstream Partners LP. We believe that the purchase has significantly strengthened Williams Companies’ midstream business. Backed by this acquisition, Williams Companies should be able to generate higher cash flow and hike dividend over the next several years. However, we remain worried as the company has a high debt burden, which might restrict its near-term growth prospects. Therefore, we are maintaining our Neutral recommendation on the company’s shares.”

Williams-Sonoma (NYSE:WSM) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $74.00 price target on the stock. Zacks’ analyst wrote, “We are initiating coverage on Williams-Sonoma with a Neutral recommendation. The leading specialty retailer of home furnishing products enjoys strong international presence and is fast expanding its international footprint. Product innovation, personalized service and strong marketing and execution have helped the company deliver strong revenues and profits since late 2011. In the first quarter of 2014, the company’s revenues and earnings exceeded the Zacks Consensus Estimate on the back of strong sales from newly acquired brands. However, with the U.S. residential activity slowing down since the second half of 2013, the demand for William Sonoma’s products could be hurt in future quarters. We therefore have a Neutral recommendation on the stock with a target price of $74.00. “

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.